Efficacy And Safety ConcernsSkeptics question the reliability of smaller N, single-arm Phase 2 data and whether better efficacy can come without greater on-target toxicities.
Market VolatilityMarket volatility is noted as a risk factor that could impact Immunome, Inc.'s stock performance.
Regulatory HurdlesConcerns are raised about the potential regulatory hurdles Immunome, Inc. may face with upcoming product approvals.